Abstract:Anaplastic lymphoma kinase rearranged (ALK+) non–small-cell lung cancer demonstrates remarkable sensitivity to crizotinib.1Camidge DR Bang YJ Kwak EL et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012; 13: 1011-1019Abstract Full Text Full Text PDF PubMed Scopus (1064) Google Scholar Although other methods exist, the dominant method for determining ALK positivity uses the Abbott (Abbott Molecular, Des Plaines, IL) ALK break-apart fluorescent in situ hybridization (FISH) assay.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar The assay has clearly defined positivity criteria but borderline or atypical negative cases occur. Here we describe a case with an atypical negative FISH result that was later confirmed as ALK+ by both immunohistochemistry (IHC) and reverse transcription polymerase chain reaction (RT-PCR)and responded well to crizotinib. A 44-year-old Chinese man with a 7 pack-year smoking history was referred to Shanghai Pulmonary Hospital in February 2013 for a left upper lobe lung mass with multiple bilateral intrapulmonary metastases, left pleural effusion, and 2R/4R/10L/11L lymphadenopathy. Pleural fluid cytology revealed adenocarcinoma and Scorpion Amplification Refractory Mutation system (AmoyDx Co., Xiamen, China). showed no detectable epidermal growth factor receptor mutation. He commenced chemotherapy with gemcitabine and cisplatin. However, after a single cycle, his symptoms worsened and imaging confirmed progressive disease. A second opinion was requested from the University of Colorado and a computed tomography–guided biopsy of the left upper lobe lesion was performed to permit additional molecular testing. In the interim, the patient commenced pemetrexed and nedaplatin. Unfortunately, after two cycles his shortness of breath worsened, with evidence of further progression on his scans (Fig. 1A). Molecular testing on his repeat biopsy specimen revealed no mutations by SNaPshot multiplex PCR testing (Life Technologies, Carlsbad, CA). However, although technically negative, the ALK break-apart FISH test showed an atypical negative pattern. Specifically, 68% of cells demonstrated single copies of the 5′ ALK signal and numerous cells with doublets of the 5′ ALK signal combined with one 3′ ALK signal (Fig. 2A). Subsequently, confirmatory diagnostic assays demonstrated ALK protein expression by IHC using the D5F3 antibody (Cell Signaling Technology Inc., Danvers, MA; H score = 150; Fig. 2B) and the presence of an echinoderm microtubule-associated protein-like 4 (EML4)-ALK transcript (E13;A20) by RT-PCR (Fig. 2C). The patient then received crizotinib (250 mg twice daily) as third-line therapy in May 2013 with an impressive symptomatic improvement and CT response after 1 month of therapy (Fig. 1B). He remains on treatment with crizotinib with no evidence of progression as of September 2013. Isolated 5′ ALK signals have previously been reported, although, because the 5′ probe is not located in the kinase region of ALK, these are usually considered ALK negative by FISH.3Yoshida A Tsuta K Nitta H et al.Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas.J Thorac Oncol. 2011; 6: 1677-1686Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar,4Camidge DR Kono SA Flacco A et al.Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.Clin Cancer Res. 2010; 16: 5581-5590Crossref PubMed Scopus (297) Google Scholar Our patient showed multiple single copies of the 5′ ALK signal plus additional 5′ doublets combined with 3′ signals, suggesting the possibility of a complex rearrangement. ALK positivity was confirmed by both IHC and RT-PCR and the patient responded well to crizotinib. A complex rearrangement generating a different atypical negative FISH pattern (3′ doublets fused with 5′ signals) that also harbored a functional ALK fusion was recently described.5Peled N Palmer G Hirsch FR et al.Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.J Thorac Oncol. 2012; 7: e14-e16Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar When FISH is the initial diagnostic assay, consideration should be given to formally defining an atypical negative ALK FISH category for additional interrogation with alternative confirmatory assays.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar

Small cell pattern of ALK-negative anaplastic large cell lymphoma with double-hit rearrangements of DUSP22 and TP63

Anaplastic Large-Cell Lymphoma with Atypical Chromosomal Translocation T(2;5) and Hypophyseal Tumor

Small cell variant of anaplastic large cell lymphoma diagnosed by a novel chromosomal abnormality t(2;5;3)(p23;q35;p21) of bone marrow cells

[Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study

ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases

Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement

ALK-negative Anaplastic Large Cell Lymphoma with Extensive Peripheral Blood and Bone Marrow Involvements Manifested As "leukemic Phase".

Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report

Systemic ALK-negative anaplastic large cell lymphoma with NPM1::TYK2 rearrangement

Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma

ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas

<i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma

ALK-positive large B-cell lymphoma showing long-term response to conventional chemoradiotherapy

Atypical Negative Alk Break-Apart Fish Harboring A Crizotinib-Responsive Alk Rearrangement in Non-Small-Cell Lung Cancer

Immunohistochemical Approach to Genetic Subtyping of Anaplastic Large Cell Lymphoma

Alk-Positive Anaplastic Large Cell Lymphoma with an Unusual Alveolar Growth Pattern

Systemic ALK-Negative Anaplastic Large Cell Lymphoma: Insights into Morphologic, Immunophenotypic, Genetic and Molecular Characteristics

ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern

Prognostic factors for primary cutaneous anaplastic large-cell lymphoma: a multicentre retrospective study from Japan

ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis